Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
82.23
+2.01 (2.51%)
Jan 22, 2025, 3:00 PM EST
Novo Nordisk Revenue
Novo Nordisk had revenue of 71.31B DKK in the quarter ending September 30, 2024, with 21.42% growth. This brings the company's revenue in the last twelve months to 270.58B, up 26.15% year-over-year. In the year 2023, Novo Nordisk had annual revenue of 232.26B with 31.26% growth.
Revenue (ttm)
270.58B DKK
Revenue Growth
+26.15%
P/S Ratio
n/a
Revenue / Employee
4.21M DKK
Employees
64,319
Market Cap
359.92B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Novo Nordisk News
- 12 hours ago - Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about Securities Fraud Investigation - NVO - Accesswire
- 1 day ago - Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate - Benzinga
- 1 day ago - IMMvention Therapeutix enters collaboration with Novo Nordisk for sickle cell disease therapies - Seeking Alpha
- 1 day ago - IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases - GlobeNewsWire
- 1 day ago - Novo Nordisk A/S Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NVO - Accesswire
- 1 day ago - Moody's Upgrades Novo Nordisk's Credit Rating Amid Strong Growth - GuruFocus
- 2 days ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 2 days ago - There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation - CNBC